Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.79
-2.3%
$4.53
$1.72
$8.21
$660.33M2.183.40 million shs3.02 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$13.25
+1.6%
$9.56
$5.31
$13.79
$657.24M1.75623,645 shs582,609 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$1.70
+6.3%
$1.69
$1.33
$3.10
$168.58M0.08740,207 shs626,017 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.12
+0.6%
$9.89
$7.16
$13.16
$653.22M0.881.18 million shs1.02 million shs
10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-2.32%-8.23%-13.67%-30.20%+51.60%
CryoPort, Inc. stock logo
CYRX
CryoPort
+1.61%+4.41%+37.45%+60.80%+89.83%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
+6.25%-1.16%-5.56%+22.30%+11.11%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
+0.63%-1.16%+14.40%+32.38%+41.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.79
-2.3%
$4.53
$1.72
$8.21
$660.33M2.183.40 million shs3.02 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$13.25
+1.6%
$9.56
$5.31
$13.79
$657.24M1.75623,645 shs582,609 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$1.70
+6.3%
$1.69
$1.33
$3.10
$168.58M0.08740,207 shs626,017 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.12
+0.6%
$9.89
$7.16
$13.16
$653.22M0.881.18 million shs1.02 million shs
10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-2.32%-8.23%-13.67%-30.20%+51.60%
CryoPort, Inc. stock logo
CYRX
CryoPort
+1.61%+4.41%+37.45%+60.80%+89.83%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
+6.25%-1.16%-5.56%+22.30%+11.11%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
+0.63%-1.16%+14.40%+32.38%+41.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.80
Moderate Buy$12.78237.14% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.89
Moderate Buy$14.448.96% Upside
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.63
Moderate Buy$7.25326.47% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.89
Moderate Buy$23.33109.83% Upside

Current Analyst Ratings Breakdown

Latest PRQR, CTMX, CYRX, and ZVRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/11/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Lower Price TargetBuy$17.00 ➝ $11.00
5/8/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
UpgradeHold (C+)Buy (B-)
5/8/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$23.00 ➝ $25.00
5/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeSell (D+)Hold (C-)
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$11.00 ➝ $12.00
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $17.00
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$13.00 ➝ $15.00
4/21/2026
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Reiterated RatingSell (D-)
4/9/2026
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Reiterated RatingBuy$4.00
3/30/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Initiated CoverageBuy$15.00
3/27/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingSell (D+)
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$76.20M8.46N/AN/A$1.88 per share2.02
CryoPort, Inc. stock logo
CYRX
CryoPort
$182.94M3.65N/AN/A$8.94 per share1.48
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$17.99M9.96N/AN/A$0.53 per share3.21
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$106.47M6.17$0.95 per share11.68$3.48 per share3.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%N/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.359.81N/AN/A41.57%-7.92%-4.79%N/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$47.73M-$0.46N/AN/AN/A-255.83%-65.89%-31.53%5/14/2026 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$83.23M$1.995.599.34N/A101.58%51.49%28.86%N/A

Latest PRQR, CTMX, CYRX, and ZVRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.15-$0.15N/A-$0.15$5.19 million$2.35 million
5/7/2026Q1 2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million
5/6/2026Q1 2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$0.06$0.18+$0.12$0.60$31.96 million$36.22 million
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
3/16/2026Q4 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million
3/12/2026Q4 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.08-$0.09-$0.01-$0.09$6.12 million$5.53 million
3/3/2026Q4 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.19-$0.21-$0.02-$0.27$42.92 million$45.45 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
10.38
3.09
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
3.09
3.09
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/A
4.89
4.84

Institutional Ownership

CompanyInstitutional Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170170.19 million158.96 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.36 million96.51 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2059.12 million57.70 millionOptionable

Recent News About These Companies

Zevra Therapeutics: Q1 Earnings Snapshot
Zevra Therapeutics Q1 Earnings Call Highlights
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$3.79 -0.09 (-2.32%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$3.78 -0.02 (-0.40%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$13.25 +0.21 (+1.61%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$13.25 0.00 (0.00%)
As of 05:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$1.70 +0.10 (+6.25%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$1.70 0.00 (0.00%)
As of 05/13/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$11.12 +0.07 (+0.63%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$11.11 -0.01 (-0.10%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.